
News|Videos|October 21, 2020
Expert Update on Lp(a): Dr Patrick Moriarty Explains the Next CVD Target
Author(s)Grace Halsey
Elevated lipoprotein A is a genetically determined independent risk factor for CVD, affecting up to 30% of the population. Phase 3 trials for the first treatment are underway.
Advertisement
________________________________________________________________
Patrick M Moriarty, MD, is professor of medicine and director of clinical pharmacology and the Atherosclerosis/Lipoprotein-Apheresis Center at the University of Kansas Medical Center, in Kansas City.
His research activities include atherosclerosis, lipid apheresis, vascular inflamation and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, obesity, hypertension, and diabetes. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
First Oral Film Treatment for Erectile Dysfunction in Men Gains FDA Approval
2
Long-Term Data Support Sustained Bimekizumab Response in Hidradenitis Suppurativa
3
Weekly Dose Podcast: New Obesity Data, Insulin Guidance, and Mental Health Screening
4
Topline Phase 2 Data Show Roflumilast Cream Improves Atopic Dermatitis in Infants as Young as 3 Months
5
































































































































